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Palliative therapy of advanced pancreatobiliary cancers is focused primarily on biliary stenting in most patients. However, biliary stent occlusion or
dysfunction is a main concern. Several types of stents are bleed designed and studied to improve stent function, but with limited success. Local ablative
therapy, such as photodynamic therapy (PDT) and radiofrequency ablation (RFA) in combination with biliary stenting is a paradigm shift in the man-
agement of advanced pancreatobiliary malignancies. The current review analyzes the data on the role of combining either PDT or RFAwith biliary stenting
in inoperable pancreatobiliary malignancies.
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The management of pancreatobiliary cancers remains a formi-
dable challenge.1 Surgery, if feasible, is the mainstay of treatment.
However, the majority of patients present in an advanced stage of
the disease, when only palliative therapy is feasible.2,3 In patients
with unresectable disease, the main objective of palliative therapy
is relief of biliary obstruction through endoscopic or radiological
techniques, which include placement of plastic biliary stents, un-
covered or covered self-expandable metallic stents (SEMS), or
percutaneous transhepatic biliary drainage.4,5 These techniques
have limited success, primarily due to stent occlusion or dysfunc-
tion. Two endoscopic modalities, photodynamic therapy (PDT) and
radiofrequency ablation (RFA), have been used recently as palliative
therapy, especially to improve stent patency.6 Themain objective of
this review is to discuss the role of PDT or RFA in combination with
biliary stenting as palliative therapy for unresectable pan-
creatobiliary cancers.
Photodynamic therapy
PDT is a well-established therapeutic modality in oncology. It
involves administration of a nontoxic photosensitizer that is pref-
erentially retained by neoplastic tissue, which in turn, on activation
by illuminating light of speciﬁc wavelength, causes ischemic ne-
crosis of tumors.7 In an animal study, PDT was shown to reduce
xenografted human cholangiocarcinoma tumor volume by more
than 50%.8 These results generated further interest in PDT. Few
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ing.9–12 The results showed improvement in cholestasis and sur-
vival with few complications. Ortner et al13 published a ﬁrst
randomized prospective study comparing PDT in addition to biliary
stenting with stenting alone. The results of this study were so
impressive in favor of PDT with stenting, the study was terminated
prematurely. However, this study has a major limitation because it
included the majority of those patients in whom technically suc-
cessful biliary stenting did not result in successful biliary drainage.
Subsequently, Kahaleh et al14 compared efﬁcacy of PDT with biliary
stenting with biliary stenting alone in patients with unresectable
cholangiocarcinoma. Their results were similar (median survival
16.2 months vs. 7.4 months, P < 0.04) to those of Ortner et al,13 in
which signiﬁcant median survival was observed after PDT (16.4
months vs. 3.3 months, P< 0.0001). However, patients in this study
were different from those in the study of Ortner et al,13 because all
patients who underwent both successful or unsuccessful biliary
drainage were included.
PDT has also been used as ablative therapy in inoperable
pancreatic ductal adenocarcinoma. In a previous study of 16 pa-
tients with inoperable pancreatic carcinoma, substantial tumor
necrosis was shown in all patients.15 Median survival after PDT was
9.5 months. Seven of 16 patients (44%) were alive 1 year after PDT.
Signiﬁcant gastrointestinal bleeding from the gastroduodenal ar-
tery developed in two patients and was managed endoscopically.
Tumors of the head of the pancreas commonly cause distal
biliary obstruction, which is managed by endoscopic biliary stent-
ing using either plastic or SEMS in most cases. The patency of SEMS
is a major challenge. Local ablative techniques such as PDT havedia
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promising results. However, the results are still conﬂicting.Fig. 1. Before radiofrequency ablation (A) Cholangiogram shows biliary stricture. (B)
Cholangioscopic image also shows biliary stricture.Radiofrequency ablation
RFA is an effective local ablative therapy that has been used
extensively in many solid organ malignancies, especially in hepa-
tocellular carcinoma. It works by emitting heat energy via a bipolar
probe by using high-frequency alternating current, which in turn
causes localized tissue necrosis. Previous studies using percuta-
neous and intraoperative RFA in unresectable cholangiocarcinoma
and pancreatic cancer have shown impressive results and signiﬁ-
cant survival advantage over both chemotherapy and supportive
care.16 Recently, there is a growing interest in the role of RFA in
palliation of pancreatobiliary cancers with the advent of endo-
scopic RFA catheters. There are two types of endobiliary RFA probes
currently available; Habib Endo HPB (EMcision, London, UK) and
Endobilary RFA catheter (Starmed, Seoul, Korea). Both are wire–
guided, bipolar probes that can be passed through the working
channel of a therapeutic duodenoscope.
Steel et al17 published their experience of treating endobiliary
RFA in 22 patients withmalignant biliary obstruction (16 pancreatic
patients and 6 cholangiocarcinoma patients). Deployment of the
RFA catheter was successful in 21 patients. Biliary SEMS were
placed in all patients after RFA. One patient failed to demonstrate
successful biliary drainage after SEMS placement. All other patients
maintained stent patency at 30 days. At 90 days follow up, stent
occlusion developed in three patients and one more patient died.
Since then, few other series have demonstrated the safety and ef-
ﬁcacy of endobiliary RFA. Our own experience of endobiliary RFA in
inoperable pancreatobiliary tumors has been promising.18 We
performed cholangioscopic evaluation of bile ducts before and after
endobiliary RFA in patients with inoperable cholangiocarcinoma
(Figs. 1 and 2). Signiﬁcant resolution of biliary stricture occured.
The ﬁrst application of RFA in an animal pancreas was reported
in 1999 and was found to be safe.19 However, the results of early
clinical applications of RFA in a human pancreas were disap-
pointing and were associated with high morbidity (up to 40%) and
mortality (up to 25%).20–25 Most of the complications arose as a
result of inadvertent injury to adjacent structures. Subsequently,
based on the thermal kinetics of RFA, the temperature settings of
RFA were changed and reduced from 105C to 90C. This change
signiﬁcantly decreased RFA-related complications.26
Deployment of SEMS is the standard of care for patients with
inoperable malignant biliary obstruction if life expectancy is >3
months. However, stent occlusion remains a problem that requires
further interventions in >50% of patients. To maintain patency of
SEMS, several therapeutic options have been studied, such as
placements of another SEMS or plastic stent, PTD and RFA. Endo-
scopically applied RFA combined with biliary SEMS has been found
to be well tolerated, safe, and appears to improve stent
patency.16,21,22 We would further emphasize that endobiliary RFA
has been applied in the management of inoperable chol-
angiocarcinoma and pancreatic cancer.
Although RFA is a user-friendly technique, it has some limita-
tions. Because RFA causes coagulative necrosis of tissue by direct
contact, there is a possibility of incomplete contact of the lesion
with the probe, which may affect the efﬁcacy of the procedure. As
demonstrated earlier, there is a linear relationship between energy
delivered and depth of ablation. However, there is no standardized
optimal dose of thermal energy and duration. Most of the studies
have used RFA generator settings as recommended by the beneﬁ-
ciary. One interesting observation in these studies is improvement
in survival.26,27This observation needs further validation. To understand the
mechanism and effect of RFA as ablative therapy, one must look
beyond local thermal injury. In this regard, the role of proin-
ﬂammatory cytokines and immunemodulation needs to be studied
further. We would also like to emphasize that there is a need to
generate more data.
PDT versus RFA
Both PDT and RFA have been used as ablative therapy with and
without stent placement. Both modalities have advantages and
limitations. PDT has been used more extensively and showed sig-
niﬁcant improvement in survival and relief from cholestasis.
However, the high cost and photosensitivity are major limitations
of PDT. By contract endobiliary RFA is evolving and many studies
are underway as the more data are needed. The major advantages
of RFA are its relatively low cost and user-friendly technique. In a
recent study, Strand et al27 compared overall survival in 48 patients
with unresectable cholangiocarcinoma who underwent palliative
endoscopic retrograde cholangiopancreatography-directed RFA (16
patients) versus PDT (32 patients).27 Overall, survival of patients
who underwent RFA was similar to that of those who underwent
Fig. 2. After radiofrequency ablation (A) Cholangiogram shows improvement of biliary
stricture. (B) Cholangioscopic image also shows improvement of biliary stricture.
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difference in the cost of PDT and RFA. Though there were more
episodes of stent occlusion and cholangitis in the RFA group, yet
other adverse events were low and comparable in both groups. The
major limitation of this study is retrospective analysis, single center
experience, and small sample size. Currently, there is no random-
ized controlled prospective study in this area. Hence, there are still
several unanswered questions. Should all patients of unresectable
cholangiocarcinoma be offered local ablative therapy? Is ablative
therapy combined with biliary stent superior to stenting alone?
Does the site of cholangiocarcinoma affect the result of therapy?
What are the predictors of response? We need more robust data to
answer all these questions. In a recent editorial, we have argued
that there is a need to go beyond biliary stenting in advanced
cholangiocarcinoma.28Conclusion
Both PDT and endobiliary RFA are effective palliative therapy in
advanced inoperable malignant biliary obstruction. The deploy-
ment of biliary plastic or SEMS is the standard of care forunresectable malignant biliary obstruction. Hence, combining local
ablative therapy with biliary stenting is a rational approach. How-
ever, there is a need to generate more data.
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